Abstract 2475: MB5029: A novel anti-PD-1 x IL-2v with improved safety profile and enhanced anti-tumor efficacy by selectively targeting activated T cells
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-2475
Abstract: Interleukin-2 (IL-2) offers therapeutic potential for cancer treatment, however, its clinical application is limited due to systemic adverse effects, such as vascular leakage syndrome (VLS). Notably, the high affinity of IL-2 for the IL-2 receptor… read more here.
Keywords: mb5029; tumor; tumor efficacy; anti tumor ... See more keywords